

IMPROVED ORAL DELIVERY OF PEPTIDES

RELATED APPLICATION

This application is based upon and claims priority to
U.S. Provisional Application Serial No. 60/441,856, filed
5 January 21, 2003.

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates to orally administered
peptide pharmaceuticals where the active compounds include
10 a plurality of amino acids and at least one peptide bond
in their molecular structures, and to methods of enhancing
bioavailability of such peptide active compounds when
administered orally.

DESCRIPTION OF THE RELATED ART

15 Numerous human hormones, neurotransmitters,
cytokines, growth factors and other important biological
compounds have peptides as a substantial part of their
molecular structures. Many diseases respond positively to
raising the level of these peptide compounds in patients.
20 Therapeutically effective amounts of such biologically
relevant peptides may be administered to patients in a
variety of ways. However, as discussed further below,
preferred oral administration is very difficult with this

type of active compound.

Salmon calcitonin, for example, is a peptide hormone which decreases calcium release from bone. When used to treat bone-related diseases and calcium disorders (such as
5 osteoporosis, Paget's disease, hypercalcemia of malignancy, and the like), it has the effect of helping maintain bone density. Many types of calcitonin have been isolated (human calcitonin, salmon calcitonin, eel calcitonin, elkatonin, porcine calcitonin, and chicken
10 calcitonin). There is significant structural non-homology among the various calcitonin types. For example, there is only 50% percent identity between the amino acids making up human calcitonin and those making up salmon calcitonin. Notwithstanding the difference in molecular structure,
15 salmon calcitonin may be used in the human treatment of the calcitonin-responsive diseases discussed above.

Another example of peptide hormone is parathyroid hormone (PTH). PTH is produced by the parathyroid gland and is a major regulator of blood calcium levels. PTH is
20 a polypeptide and synthetic polypeptides may be prepared by the method disclosed by Erickson and Merrifield, The Proteins, Neurath et al, Eds., Academic Press, New York, 1976, page 257, and as modified by the method of Hodges et al (1988), Peptide Research 1, 19, or by Atherton, E. and
25 Sheppard, R. C., Solid Phase Peptide Synthesis, IRL Press, Oxford, 1989.

When serum calcium is reduced to below a normal level, the parathyroid gland releases PTH and the calcium level is increased by resorption of bone calcium, by increased absorption of calcium from the intestine, and by
5 increased renal reabsorption of calcium from nascent urine in the kidney tubules. Although continuously infused low levels of PTH can remove calcium from the bone, the same low doses, when intermittently injected can actually promote bone growth.

10 Tregear, U.S. Pat. No 4,086,196, described human PTH analogues and claimed that the first 27 to 34 amino acids are the most effective in terms of the stimulation of adenylyl cyclase in an in vitro cell assay. Rosenblatt, U.S. Pat. No. 4,771,124, disclosed the property of hPTH
15 analogues wherein Trp²³ is substituted by amino acids phenylalanine, leucine, norleucine, valine, tyrosine, β -naphthylalanine, or α -naphthylalanine as a PTH antagonist. These modified hPTH analogues also have the 2 and 6 amino terminal acids removed, resulting in loss of
20 most agonist activities when used to treat osteoporosis. These analogues were designed as inhibitors of PTH and PTH-related peptides. The analogues were claimed as possibly useful in the treatment of hypercalcemia associated with some tumors.

25 Pang et al, WO93/06845, published April 15, 1993, described analogues of hPTH which involve substitutions of

Arg²⁵, Lys²⁶, Lys²⁷ with numerous amino acids, including alanine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine. These are claimed to be effective in the treatment of osteoporosis with minimal effects on blood pressure and smooth muscle.

PTH operates through activation of two second messenger systems, G_s -protein activated adenylyl cyclase (AC) and G_q -protein activated phospholipase C_β. The latter results in a stimulation of membrane-bound protein kinase Cs (PKC) activity. The PKC activity has been shown to require PTH residues 29 to 32 (Jouishomme et al (1994) J. Bone Mineral Res. 9, (1179-1189). It has been established that the increase in bone growth, i.e., that effect which is useful in the treatment of osteoporosis, is coupled to the ability of the peptide sequence to increase AC activity. The native PTH sequence has been shown to have all of these activities. The human hPTH-(1-34) sequence is typically shown as:

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His
Leu Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu
Gln Asp Val His Asn Phe-OH (SEQ ID NO:1).

Various PTH analogues are disclosed in U.S. patent Nos. 5,955,425 and 6,110,892. The following linear

analogue (truncated hPTH), hPTH-(1-31)-NH₂, has only AC-stimulating activity and has been shown to be fully active in the restoration of bone loss in the ovariectomized rat model (Rixon, R. H. et al (1994) J. Bone Miner. Res. 9, 1179-1189; Whitfield et al (1996), Calcified Tissue Int. 58, 81-87; and Willick et al, U.S. Pat. No. 5,556,940):

Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His
Leu Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu
Gln Asp Val-NH₂ (SEQ ID NO:2).

10 Peptide pharmaceuticals used in the prior art
frequently have been administered by injection or by nasal
administration. Insulin is one example of a peptide
pharmaceutical frequently administered by injection. A
more preferred and convenient oral administration tends to
15 be problematic because peptide active compounds are very
susceptible to degradation in the stomach and intestines.
For example, while the prior art has reported an ability
to achieve reproducible blood levels of salmon calcitonin
and parathyroid hormone when administered orally, these
20 levels are low. This is believed to be because these
peptide hormones lack sufficient stability in the
gastrointestinal tract, and tend to be poorly transported
through intestinal walls into the blood. However,
injection and nasal administration are significantly less
25 convenient than, and involve more patient discomfort than,
oral administration. Often this inconvenience or

discomfort results in substantial patient noncompliance with a treatment regimen. Thus, there is a need in the art for more effective and reproducible oral administration of peptide pharmaceuticals like insulin, salmon calcitonin, parathyroid hormone and others discussed in more detail herein.

Proteolytic enzymes of both the stomach and intestines may degrade peptides, rendering them inactive before they can be absorbed into the bloodstream. Any amount of peptide that survives proteolytic degradation by proteases of the stomach (typically having acidic pH optima) is later confronted with proteases of the small intestine and enzymes secreted by the pancreas (typically having neutral to basic pH optima). Specific difficulties arising from the oral administration of a peptide like salmon calcitonin involve the relatively large size of the molecule, and the charge distribution it carries. This may make it more difficult for salmon calcitonin to penetrate the mucus along intestinal walls or to cross the intestinal brush border membrane into the blood.

One way to improve the effectiveness of oral administration of peptides is to protect them from proteolytic enzymes in the stomach and intestine as well as enhance their absorption from the intestine thereby enhancing their bioavailability. Improving oral effectiveness is important for several reasons. First,

peptides and proteins are expensive to manufacture either by chemical synthesis or recombinant DNA technologies. Therefore, the more one increases bioavailability, the lesser the amounts that will be required in an oral
5 formulation of a therapeutic drug.

Second, the greater the bioavailability of an oral peptide, the less the variability in the dosage absorbed by an individual on a day to day basis.

Third, the greater the bioavailability of an oral
10 peptide, the less the concern about breakdown products of the peptide since such breakdown products can act as agonists or antagonists of the receptors where the peptide binds to elicit biological activity.

SUMMARY OF THE INVENTION

15 It is accordingly an object of the present invention to provide a therapeutically effective oral pharmaceutical composition for reliably delivering pharmaceutical peptides, e.g., physiologically active peptide agents such as insulin, salmon calcitonin, parathyroid hormone,
20 vasopressin, or analogs thereof and others discussed herein.

It is a further object of the invention to provide therapeutic methods for enhancing the bioavailability of such peptides.

It is a further object of the invention to provide methods of treating bone-related diseases and calcium disorders by administering salmon calcitonin or PTH 1-31NH₂ orally.

5 In one aspect, the invention provides a pharmaceutical composition for oral delivery of a physiologically active peptide agent comprising a therapeutically effective amount of said active peptide, wherein said active peptide is amidated at a location that
10 is not naturally amidated.

Preferred peptide active agents include but are not limited to insulin, vasopressin, salmon calcitonin, glucagon-like peptide 1 or 2, parathyroid hormone, luteinizing hormone releasing hormone, erythropoietin, and
15 analogs thereof. Especially preferred is parathyroid hormone and analogs thereof.

In another aspect, the invention provides a method for enhancing the bioavailability of a therapeutic peptide active agent delivered orally, said method comprising
20 amidating said peptide agent.

The present invention is believed to reduce the likelihood of proteolytic degradation of the peptide active compound by simultaneously protecting the peptide from proteolytic attack by (1) stomach proteases which are

typically most active at acidic pHs and (2) intestinal or pancreatic proteases (which are typically most active at basic to neutral pH).

Also, the invention is believed to promote the
5 process by which the peptide crosses the intestinal brush border membrane into the blood due to the presence of amide, while continuing to protect the peptide from proteolytic degradation.

An acid resistant protective coating of the capsule
10 or tablet protects the peptide active agent from the acid-acting proteases of the stomach. Thereafter, after the formulation passes into the intestine where the pH is less acidic, the enteric coating dissolves to release the contents of the formulation. Significant quantities of
15 acid (with which the peptide active agent is intermixed) reduce the activity of neutral to basic-acting proteases (e.g., luminal or digestive proteases and proteases of the brush border membrane) by lowering pH locally at the site of release of the formulation below their optimal activity
20 range.

Other features and advantages of the present invention will become apparent from the following detailed description of the invention.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the invention, patients in need of treatment with peptide active ingredients are provided with an oral pharmaceutical composition thereof (at
5 appropriate dosage), preferably but not necessarily in tablet or capsule form of an ordinary size in the pharmaceutical industry. The dosages and frequency of administering the products are discussed in more detail below. Patients who may benefit are any who suffer from
10 disorders that respond favorably to increased levels of a peptide-containing compound. For example, oral salmon calcitonin in accordance with the invention may be used to treat patients who suffer from calcium disorders or bone diseases. The invention may be used, for example, to
15 treat osteoporosis, Paget's disease, hypercalcemia of malignancy and the like, with oral calcitonin, oral parathyroid hormone, preferably hPTH 1-31NH₂ and hPTH 1-34NH₂.

Salmon calcitonin is a preferred active ingredient
20 for use in accordance with the invention for a number of reasons. For example, it provides a number of advantages over even human calcitonin, even though used as a pharmaceutical agent for human patients. Among the advantages provided by utilizing salmon calcitonin instead
25 of human calcitonin for the treatment of human osteoporosis are increased potency, analgesia and increased half-life. Salmon calcitonin is more effective

than natural human calcitonin in treatment, since lower dosages are necessary than with human calcitonin. There is substantial non-homology between salmon and human calcitonin, with only 50% identity in the amino acid sequences of the two calcitonins.

Without intending to be bound by theory, the pharmaceutical composition of the invention is believed to overcome a series of different and unrelated natural barriers to bioavailability. Various components of the pharmaceutical compositions act to overcome different barriers by mechanisms appropriate to each, and result in synergistic effects on the bioavailability of a peptide active ingredient.

The peptide active compound may be administered orally. In accordance with the invention, the presence of at least one amide group would protect the peptide or protein from proteolytic degradation, thereby improving bioavailability. The amide group may also enhance the membrane permeability of the protein across the lumen of the intestine. Other mechanisms for increase in bioavailability by the presence of the amide group may also be possible.

Various techniques exist for recombinant production of peptide products, i.e. any compound whose molecular structure includes a plurality of amino acids linked by a

peptide bond.

Overview of a Preferred Expression Vector

A preferred expression vector is described in US Patent No. 6,210,925 and is incorporated herein by
5 reference. An example of a preferred vector for expressing salmon calcitonin is shown in Figure 9 of US Patent No. 6,210,925. For the expression of other peptide products, a nucleic coding for the desired peptide product would be substituted for the nucleic acid coding for
10 salmon calcitonin.

The preferred expression vector comprises a coding region and a control region. The coding region comprises nucleic acids for a peptide product of interest coupled in reading frame downstream from nucleic acids coding for a
15 signal peptide. The control region is linked operably to the coding region and comprises a plurality of promoters and at least one ribosome binding site, wherein at least one of the promoters is selected from the group consisting of tac and lac.

20 Preferably, the vector comprises a plurality of transcription cassettes placed in tandem, each cassette having the control region and the coding region of the present invention. Such a digenic vector or multigenic vector is believed to provide better expression than would
25 a dicistronic or multicistronic expression vector. This

is a surprising improvement over dicistronic or multicistronic expression which is not believed to be suggested by the prior art.

The vector can optionally further comprise nucleic acids coding for a repressor peptide which represses operators associated with one or more of the promoters in the control region, a transcription terminator region, a selectable marker region and/or a region encoding at least one secretion enhancing peptide. Alternatively, in some embodiments, nucleic acids coding for a repressor peptide and a secretion enhancing peptide may be present on a separate vector co-expressed in the same host cell as the vector expressing the peptide product.

Many commercially available vectors may be utilized as starting vectors for the preferred vectors of the invention. Some of the preferred regions of the vectors of the invention may already be included in the starting vector such that the number of modifications required to obtain the vector of the invention is relatively modest.

20 The control region

The control region is operably linked to the coding region and comprises a plurality of promoters and at least one ribosome binding site, wherein at least one of the promoters is selected from the group consisting of lac and tac. The foregoing combination of promoters in a single

control region significantly increases yield of the peptide product produced by the coding region (as described in more detail infra). Other promoters are known in the art, and may be used in combination with a
5 tac or lac promoter. Such promoters include but are not limited to lpp, ara B, trpE, gal K.

Preferably, the control region comprises exactly two promoters. When one of the promoters is tac, it is preferred that the tac promoter be 5' of another promoter
10 in the control region. When one of the promoters is lac, the lac promoter is preferably 3' of another promoter in the control region. Also preferably, the control region comprises both a tac promoter and a lac promoter, preferably with the lac promoter being 3' of the tac
15 promoter.

The coding region

The coding region comprises nucleic acids coding for a peptide product of interest coupled in reading frame downstream from nucleic acids coding for a signal peptide
20 whereby the coding region encodes a peptide comprising, respectively, from N terminus to C terminus the signal and the peptide product. Without intending to be bound by theory, it is believed that the signal may provide some protection to the peptide product from proteolytic
25 degradation in addition to participating in its secretion to the periplasm.

Many peptide signal sequences are known and may be used in accordance with the invention. These include signal sequences of outer membrane proteins of well-characterized host cells, and any sequences capable of
5 translocating the peptide product to the periplasm and of being post-translationally cleaved by the host as a result of the translocation. Useful signal peptides include but are not limited to Omp A, pel B, Omp C, Omp F, Omp T, β -la, Pho A, Pho S and Staph A.

10 The peptide product is preferably small enough so that it would usually require a fusion partner using prior art technology. Typically, the peptide product has a molecular weight of less than 10 KDa. More preferably, the peptide product has a C-terminal glycine, and is used
15 as a precursor to an enzymatic amidation reaction converting the C-terminal glycine to an amino group, thus resulting in an amidated peptide. Such a conversion is described in more detail infra. Numerous biologically important peptide hormones and neurotransmitters are
20 amidated peptides of this type. For example, the peptide product coded by the coding region may be salmon calcitonin precursor or calcitonin gene related peptide precursor, both of which have C-terminal glycines and both of which may be enzymatically amidated to mature salmon
25 calcitonin or mature calcitonin gene related peptide.

Analog of parathyroid hormone could also be produced

in accordance with the invention. For example, a peptide having the first 34 amino acids of parathyroid hormone can provide a function similar to that of parathyroid hormone itself, as may an amidated version of the 34 amino acid analog. The latter may be produced by expressing, in accordance with one or more of the expression systems and methods described herein, the first 34 amino acids of parathyroid hormone, followed by glycine-35. Enzymatic amidation as disclosed herein could then convert the glycine to an amino group.

Other Optional Aspects of a Preferred Vector of
The Invention or of Other Vectors to be Expressed
in the Same Host as the Vector of the Invention

Repressor

Optionally, the preferred vector may contain nucleic acids coding for a repressor peptide capable of repressing expression controlled by at least one of the promoters. Alternatively, however, the nucleic acids coding for a repressor peptide may be present on a separate vector in a host cell with the vector of the present invention. Appropriate repressors are known in the art for a large number of operators. Preferably, the nucleic acids coding for the repressor encode a lac repressor in preferred embodiments of the invention because it represses the lac operator that is included with both tac and lac promoters, at least one of which promoters is always present in preferred vectors of the invention.

Selectable marker

It is preferred that any of a large number of selectable marker genes (e.g. a gene encoding kanamycin resistance) be present in the vector. This will permit
5 appropriate specific selection of host cells that are effectively transformed or transfected with the novel vector of the invention.

Secretion enhancing peptide

Nucleic acids coding for at least one secretion
10 enhancing peptide are optionally present in the vector of the present invention. Alternatively, the nucleic acids coding for a secretion enhancing peptide may be present on a separate vector expressed in the same host cell as the vector encoding the peptide product. Preferably, the
15 secretion enhancing peptide is selected from the group consisting of SecY (prlA) or prlA-4. It is pointed out that SecY and prlA are identical, the two terms being used as synonyms in the art. prlA-4 is a known modification of prlA and has a similar function. Another preferred
20 secretion enhancing peptide is SecE also known as "prlG", a term used as a synonym for "SecE". Most preferably, a plurality of secretion enhancing peptides are encoded, at least one of which is SecE and the other of which is
25 prlA-4. The two are believed to interact to aid translocation of the peptide product from cytoplasm to periplasm. Without intending to be bound by theory, these

secretion enhancing peptides may help protect the peptide product from cytoplasmic proteases in addition to their secretion enhancing functions.

Amidation of peptides and proteins, preferably at the C-terminus, affords a significant increase in oral bioavailability as demonstrated hereinbelow. The prior art indicates that natural amidation of biologically active peptides may increase receptor binding and improve the stability of these peptides (Eipper et al., Annu. Rev. Neurosci., 15:57-85, 1992; Merkler, Enzyme Micob. Technol., 16:450-456, particularly page 51, 1994). The significant increase in bioavailability afforded by amidation of these peptides was unexpected, since current knowledge states that the primary determinants of oral bioavailability of peptides and proteins are the size, the secondary and tertiary structure, and the charge of the molecules.

Normally, the plasma membrane of eukaryotic cells is impermeable to large peptides or proteins. However, certain hydrophobic moieties such as amino acid sequences, fatty acids and bile acids variously called ferry peptides or membrane translocating sequences or moieties, when fused to the functional proteins or peptides, in particular to the N- or C- terminus, can act as membrane translocators, and mediate the transport of these proteins into living cells. These membrane translocators (MTs) for

the purpose of the present invention are capable of being at least partially cleaved by a blood or lymphatic system protease.

In accordance with another aspect of the invention,
5 the presence of at least one membrane translocator (MT), preferably two MTs, more preferably, two peptide MTs would enhance the membrane permeability of the peptide fused to the MT(s) across the lumen of the intestine and provide for improved bioavailability. Since the MT link to the
10 active peptide can be cleaved by an enzyme in the blood or the lymphatic system, it leaves the active peptide free to reach its target.

Also, in accordance with the invention, proteolytic degradation of the peptide and of the membrane
15 translocator by stomach enzymes (most of which are active in the acid pH range) and intestinal or pancreatic proteases (most of which are active in the neutral to basic pH range) is reduced.

Again, without intending to be bound by theory, it
20 appears that, in accordance with the present invention, the peptide is transported through the stomach under the protection of an appropriate acid-resistant protective vehicle for substantially preventing contact between the salmon calcitonin or other active peptide and any stomach
25 proteases capable of degrading it. Once the

pharmaceutical composition of the invention passes through the stomach and enters the intestinal region where basic to neutral pH predominates, and where proteases tend to have basic to neutral pH optima, the enteric coating or other vehicle releases the peptide and acid or protease inhibitors (in close proximity to each other).

The acid is believed to lower the local intestinal pH (where the active agent has been released) to levels below the optimal range for many intestinal proteases and other intestinal enzymes. This decrease in pH reduces the proteolytic activity of the intestinal proteases, thus affording protection to the peptide and the membrane translocator from potential degradation. The activity of these proteases is diminished by the temporarily acidic environment provided by the invention. It is preferred that sufficient acid be provided that local intestinal pH is lowered temporarily to 5.5 or below, preferably 4.7 or below and more preferably 3.5 or below. The sodium bicarbonate test described below (in the section captioned "the pH-Lowering Agent") is indicative of the required acid amount. Preferably, conditions of reduced intestinal pH persist for a time period sufficient to protect the peptide agent and the membrane translocator from proteolytic degradation until at least some of the peptide agent has had an opportunity to cross the intestinal wall into the bloodstream. For salmon calcitonin, experiments have demonstrated a T_{\max} of 5-15 minutes for blood levels

of salmon calcitonin when the active components are injected directly into the duodenum, ileum or colon of rats.

Alternatively, protease inhibitors are believed to
5 reduce the proteolytic activity of the intestinal proteases, thus affording protection to the peptide and the membrane translocator from premature potential degradation.

Compositions of the present invention can optionally
10 contain absorption enhancers. The absorption enhancers of the invention synergistically promote peptide absorption into the blood while conditions of reduced proteolytic activity prevail.

The mechanism by which the invention is believed to
15 accomplish the goal of enhanced bioavailability is aided by having active components of the pharmaceutical composition released together as simultaneously as possible. To this end, it is preferred to keep the volume of enteric coating as low as possible consistent with
20 providing protection from stomach proteases. Thus enteric coating is less likely to interfere with peptide release, or with the release of other components in close time proximity with the peptide. The enteric coating should normally add less than 30% to the weight of the remainder
25 of pharmaceutical composition (i.e., the other components

of the composition excluding enteric coating).

Preferably, it is less than 20% and, more preferably, the enteric coating adds between 10% and 20% to the weight of the uncoated ingredients.

5 The absorption enhancer which may be a solubility enhancer and/or transport enhancer (as described in more detail below) aids transport of the peptide agent from the intestine to the blood, and may promote the process so that it better occurs during the time period of reduced
10 intestinal pH and reduced intestinal proteolytic activity. Many surface active agents may act as both solubility enhancers and transport (uptake) enhancers. Again without intending to be bound by theory, it is believed that enhancing solubility provides (1) a more simultaneous
15 release of the active components of the invention into the aqueous portion of the intestine, (2) better solubility of the peptide in, and transport through, a mucous layer along the intestinal walls. Once the peptide active ingredient reaches the intestinal walls, an uptake
20 enhancer provides better transport through the brush border membrane of the intestine into the blood, via either transcellular or paracellular transport. As discussed in more detail below, many preferred compounds may provide both functions. In those instances, preferred
25 embodiments utilizing both of these functions may do so by adding only one additional compound to the pharmaceutical composition. In other embodiments, separate absorption

enhancers may provide the two functions separately.

Each of the preferred ingredients of the pharmaceutical composition of the invention is separately discussed below. Combinations of multiple pH-lowering
5 agents, or multiple enhancers can be used as well as using just a single pH-lowering agent and/or single enhancer. Some preferred combinations are also discussed below.

Peptide Active Ingredients

Peptide active ingredients which may benefit from
10 oral delivery in accordance with the invention include any therapeutic agent that is physiologically active and has a plurality of amino acids and at least one peptide bond in its molecular structure and one site that can be amidated. Amidation of the peptide can be achieved either by
15 chemical or enzymatic means, or by a combination of the two. A preferred method of amidation is by the action of peptidylglycine-amidating monooxygenase.

Preferably, the peptide is extended by a glycine at the C-terminal end when produced by recombinant technology
20 and the C-terminus is amidated by enzymatic reaction. Alternatively, amino acid side chains suitable for amidation can also be amidated by chemical reaction.

Also, preferably, these peptide active ingredients are linked to an MT sequence to facilitate their

absorption from the intestine. The MT must be protected from cleavage by proteases in the stomach and intestine before its absorption. However, once absorbed, the MT should be able to be at least partially removed by
5 proteases to free up the active peptide.

The MT can comprise an amino acid sequence, preferably a signal peptide or signal sequence. A "signal peptide," as used herein, is a sequence of amino acids generally but not necessarily of a length of about 10 to
10 about 50 or more amino acid residues, many (typically about 55-60%) residues of which are hydrophobic such that they have a hydrophobic, lipid-soluble portion. The hydrophobic portion is a common, major motif of the signal peptide, and it is often a central part of the signal
15 peptide of proteins secreted from cells. A signal peptide is a sequence of amino acids that facilitates the export of cytoplasmic proteins. The signal peptides of this invention, as discovered herein, are also "importation competent," i.e., capable of penetrating through the cell
20 membrane from outside the cell to the interior of the cell. The amino acid residues can be mutated and/or modified (i.e., to form mimetics) so long as the modifications do not affect the translocation-mediating function of the peptide. Thus the word "peptide" includes
25 mimetics and the word "amino acid" includes modified amino acids, as used herein, unusual amino acids, and D-form amino acids. All importation competent signal peptides

encompassed by this invention have the function of mediating translocation across a cell membrane from outside the cell to the interior of the cell. They may also retain their ability to allow the export of a protein
5 from the cell into the external milieu. A putative signal peptide can easily be tested for this importation activity following the teachings provided herein, including testing for specificity for any selected cell type.

The following Table 1 exemplifies amino acid
10 sequences, each of which can be used as an MT.

**Table 1 - Amino Acid Sequences of Some
MT Peptides and Their Sources**

	SEQUENCE	SEQUENCE DERIVATION	SOURCE
5	ALA-ALA-VAL-ALA-LEU- LEU-PRO-ALA-VAL-LEU- LEU-ALA-LEU-LEU-ALA- PRO-VAL-ASN-ARG-LYS- ARG-ASN-LYS-LEU-MET- PRO (SEQ ID No:3)	Signal Peptide from Kaposi Fibroblast Growth Factor	U.S. Pat. 5,807,746
10	TYR-GLY-ARG-LYS-LYS- ARG-ARG-GLN-ARG-ARG- ARG (SEQ ID No:4)	Protein Transduction Domain of HIV TAT Protein	Schwarz et al. (1999), Science 285:1569
15	VAL-THR-VAL-LEU-ALA- LEU-GLY-ALA-LEU-ALA- GLY-VAL-GLY-VAL-GLY (SEQ ID No:5)	Signal Sequence of Human Integrin β_3	Zhang et al. (1988) PNAS 95:9184
	38 kDa Protein	HSV-VP22 Protein	Phelan et al. (1998), Nature Biotechnology 16:440
20	ALA-ALA-VAL-LEU-LEU- PRO-VAL-LEU-LEU-ALA- ALA-PRO (SEQ ID No:6)	Modified from 16- residue hydrophobic region of signal sequence of Kaposi fibroblast growth factor	Rojas et al (1998) Nature Biotechnology 16:370

The MT can also comprise fatty acids and/or bile acids. Such molecules, when used, are linked to the active peptide by an amino acid bridge which is subject to cleavage by proteases in the plasma. Alternatively, the MT can be linked to the active peptide by a non-peptidyl linkage, in which case the in vivo enzyme that cleaves the linkage may be an enzyme other than protease. The amino acid bridge must be a target for cleavage by at least one plasma protease. Plasma proteases as well as their target sequences are well known in the art. Table 2 illustrates

some of these enzymes as well as their specific targets

Table 2 - Plasma Proteases and their Specific Targets

	PROTEASE	SPECIFIC TARGET	REMARKS
	Caspase-1	Tyr-Val-Ala-Asp-Xaa* (SEQ ID No:7)	
5	Caspase-3	Asp-Xaa-Xaa-Asp-Xaa (SEQ ID No:8)	
	Proprotein convertase 1	Arg-(Xaa) _n -Arg-Xaa (SEQ ID No:9)	n=2, 4 or 6
		Lys-(Xaa) _n -Arg-Xaa (SEQ ID No:10)	n=2, 4, or 6
		Arg-Arg-Xaa	
		Lys-Arg-Xaa	
	Proprotein convertase 2	same as proprotein convertase 1	
10	Proprotein convertase 4	Gly-Arg-Thr-Lys-Arg-Xaa (SEQ ID No:11)	
	Proprotein convertase 4 PACE 4	Arg-Val-Arg-Arg-Xaa (SEQ ID No:12)	
		Decanoyl-Arg-Val-Arg-Arg-Xaa (SEQ ID No:13)	
	Prolyl oligopeptidase	Pro-Xaa	
15	Endothelin cleaving enzyme followed by dipeptidyl-peptidase IV	Trp-Val-Pro-Xaa (SEQ ID No:14) Trp-Val-Ala-Xaa (SEQ ID No:15)	
	Signal peptidase		depends on nearby amino acid
20	Neprilysin followed by dipeptidyl-peptidase IV	Xaa-Phe-Xaa-Xaa (SEQ ID No:16)	broad specificity, max length = 40 amino acids
		Xaa-Tyr-Xaa-Xaa (SEQ ID No:17)	

PROTEASE	SPECIFIC TARGET	REMARKS
	Xaa- Trp-Xaa -Xaa (SEQ ID No:18)	
Renin followed by dipeptidyl-peptidase IV	Asp-Arg-Tyr-Ile-Pro-Phe-His-Leu- Leu-Val-Tyr-Ser (SEQ ID No:19)	substitute Pro or Ala for Val & Ser

*The N-terminal side of bolded amino acids is the specific
5 target for the protease cleavage.

The invention, by several mechanisms, suppresses the degradation of the active ingredient by protease that would otherwise tend to cleave one or more of the peptide bonds of the active ingredient.

10 Both synthetic and natural peptides can be orally delivered in accordance with the invention. Peptide active compounds of the invention include, but are not limited to, insulin, vasopressin, calcitonin (including not only the preferred salmon calcitonin, but other calcitonins as
15 well) and parathyroid hormones and analogs thereof. Other examples include calcitonin gene-related peptide, luteinizing hormone-releasing factor, erythropoietin, tissue plasminogen activators, human growth hormone, adrenocorticototropin, various interleukins, enkephalin,
20 glucagon-like peptide 1, and all analogs thereof. Many others are known in the art. It is expected that any pharmaceutical compound having peptide bonds which would be subject to cleavage in the gastrointestinal tract would

benefit from oral delivery in accordance with the present invention because of the enhancement of absorption of such compounds from the intestine coupled with the reduction in such cleavage that is afforded by the present invention.

5 When salmon calcitonin is used, it preferably comprises from 0.02 to 0.2 percent by weight relative to the total weight of the overall pharmaceutical composition (exclusive of enteric coating) Salmon calcitonin is commercially available (for example, from BACHEM,
10 Torrence, California). Alternatively it may be synthesized by known methods, some of which are discussed briefly below. Other peptide active agents should be present at higher or lower concentrations depending on desired target blood concentrations for the active
15 compound and its bioavailability in the oral delivery system of the invention.

 Salmon calcitonin precursors may be made by either chemical or recombinant syntheses known in the art. Precursors of other amidated peptide active agents may be
20 made in like manner. Recombinant production is believed to be significantly more cost effective. Precursors are converted to active salmon calcitonin by amidation reactions that are also known in the art. For example, enzymatic amidation is described in U.S. Patent 4,708,934
25 and European Patent Publications 0 308 067 and 0 382 403. Recombinant production is preferred for both the precursor

and the enzyme that catalyzes the conversion of the precursor to salmon calcitonin. Such recombinant production is discussed in Biotechnology, Vol. 11 (1993) pp. 64-70, which further describes a conversion of a precursor to an amidated product. The recombinant product reported there is identical to natural salmon calcitonin, and to salmon calcitonin produced using solution and solid phase chemical peptide synthesis.

When an MT is linked to the active peptide ingredient of the invention, it may be made accomplished by either chemical or recombinant syntheses known in the art. By "linking" as used herein is meant that the biologically active peptide is associated with the MT in such a manner that when the MT crosses the cell membrane, the active peptide is also imported across the cell membrane. Examples of such means of linking include (A) linking the MT to the active peptide by a peptide bond, i.e., the two peptides (the peptide part of the MT and the active peptide) can be synthesized contiguously; (B) linking the MT to the active peptide by a non-peptide covalent bond (such as conjugating a signal peptide to a protein with a crosslinking reagent); (C) chemical ligation methods can be employed to create a covalent bond between the carboxy-terminal amino acid of an MT such as a signal peptide and the active peptide.

Examples of method (A) are shown below wherein a

peptide is synthesized, by standard means known in the art, (Merrifield, J. Am. Chem. Soc. 85:2149-2154, 1963; and Lin et al., Biochemistry 27:5640-5645, 1988) and contains, in linear order from the amino-terminal end, a
5 signal peptide sequence (the MT), an amino acid sequence that can be cleaved by a plasma protease, and a biologically active amino acid sequence. Such a peptide could also be produced through recombinant DNA techniques, expressed from a recombinant construct encoding the
10 above-described amino acids to create the peptide. (Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989).

For method (B), either a peptide bond, as above, can
15 be utilized or a non-peptide covalent bond can be used to link the MT with the biologically active peptide, polypeptide or protein. This non-peptide covalent bond can be formed by methods standard in the art, such as by conjugating the MT to the peptide, polypeptide or protein
20 via a crosslinking reagent, for example, glutaraldehyde. Such methods are standard in the art. (Walter et al., Proc. Natl. Acad. Sci. USA 77:5197; 1980).

For method (C), standard chemical ligation methods, such as using chemical crosslinkers interacting with the
25 carboxy-terminal amino acid of a signal peptide, can be utilized. Such methods are standard in the art (Goodfriend

et al., Science 143:1344; 1964, which uses water-soluble carbodiimide as a ligating reagent) and can readily be performed to link the carboxy terminal end of the signal peptide to any selected biologically active molecule.

5 The production of the preferred recombinant salmon calcitonin (rsCT) may proceed, for example, by producing glycine-extended salmon calcitonin precursor in *E. coli* as a soluble fusion protein with glutathione-S-transferase. The glycine-extended precursor has a molecular structure
10 that is identical to active salmon calcitonin except at the C-terminal (where salmon calcitonin terminates -pro-NH₂, while the precursor terminates -pro-gly. An α -amidating enzyme described in the publications above catalyzes conversion of precursors to salmon calcitonin.
15 That enzyme is preferably recombinantly produced, for example, in Chinese Hamster Ovary (CHO) cells) as described in the Biotechnology article cited above. Other precursors to other amidated peptides may be produced in like manner.

20 Peptides that are not amidated naturally may also be produced in like manner and amidated in a similar fashion according to the invention.

The pH-Lowering Agent and Protease Inhibitor

25 The total amount of the pH-lowering compound to be administered with each administration of salmon calcitonin

should preferably be an amount which, when it is released into the intestine, is sufficient to lower the local intestinal pH substantially below the pH optima for proteases found there. The quantity required will necessarily vary with several factors including the type of pH-lowering agent used (discussed below) and the equivalents of protons provided by a given pH-lowering agent. In practice, the amount required to provide good bioavailability is an amount which, when added to a solution of 10 milliliters of 0.1 M sodium bicarbonate, lowers the pH of that sodium bicarbonate solution to no higher than 5.5, and preferably no higher than 4.7, most preferably no higher than 3.5. Enough acid to lower pH, in the foregoing test, to about 2.8 may be used in some embodiments. Preferably at least 300 milligrams, and more preferably at least 400 milligrams of the pH-lowering agent are used in the pharmaceutical composition of the invention. The foregoing preferences relate to the total combined weight of all pH-lowering agents where two or more of such agents are used in combination. The oral formulation should not include an amount of any base which, when released together with the pH-lowering compound, would prevent the pH of the above-described sodium bicarbonate test from dropping to 5.5 or below.

The pH-lowering agent of the invention may be any pharmaceutically acceptable compound that is not toxic in the gastrointestinal tract and is capable of either

delivering hydrogen ions (a traditional acid) or of inducing higher hydrogen ion content from the local environment. It may also be any combination of such compounds. It is preferred that at least one pH-lowering agent used in the invention have a pKa no higher than 4.2, and preferably no higher than 3.0. It is also preferred that the pH lowering agent have a solubility in water of at least 30 grams per 100 milliliters of water at room temperature.

Examples of compounds that induce higher hydrogen ion content include aluminum chloride and zinc chloride. Pharmaceutically acceptable traditional acids include, but are not limited to acid salts of amino acids (e.g., amino acid hydrochlorides) or derivatives thereof. Examples of these are acid salts of acetylglutamic acid, alanine, arginine, asparagine, aspartic acid, betaine, carnitine, carnosine, citrulline, creatine, glutamic acid, glycine, histidine, hydroxylysine, hydroxyproline, hypotaurine, isoleucine, leucine, lysine, methylhistidine, norleucine, ornithine, phenylalanine, proline, sarcosine, serine, taurine, threonine, tryptophan, tyrosine and valine.

Other examples of useful pH-lowering compounds include carboxylic acids such as acetylsalicylic, acetic, ascorbic, citric, fumaric, glucuronic, glutaric, glyceric, glycolic, glyoxylic, isocitric, isovaleric, lactic, maleic, oxaloacetic, oxalosuccinic, propionic, pyruvic,

succinic, tartaric, valeric, and the like.

Other useful pH-lowering agents that might not usually be called "acids" in the art, but which may nonetheless be useful in accordance with the invention are
5 phosphate esters (e.g., fructose 1, 6 diphosphate, glucose 1, 6 diphosphate, phosphoglyceric acid, and diphosphoglyceric acid). CARBOPOL® (Trademark BF Goodrich) and polymers such as polycarbophil may also be used to lower pH.

10 Any combination of pH lowering agent that achieves the required pH level of no higher than 5.5 in the sodium bicarbonate test discussed above may be used. One preferred embodiment utilizes, as at least one of the pH-lowering agents of the pharmaceutical composition, an acid
15 selected from the group consisting of citric acid, tartaric acid and an acid salt of an amino acid.

When salmon calcitonin is the peptide active agent, certain ratios of pH-lowering agent to salmon calcitonin have proven especially effective. It is preferred that
20 the weight ratio of pH-lowering agent to salmon calcitonin exceed 200:1, preferably 800:1 and most preferably 2000:1.

An alternative or a supplement to the use of pH-lowering agents is the use of protease inhibitors, in particular inhibitors of intestinal proteases. The

following Table 3 illustrates some of the known intestinal proteases.

**Table 3 - Intestinal Proteases and
their Specific Targets**

5	PROTEASE	TARGET SITE	pH OPTIMUM	REMARKS
	Trypsin	Lys-Xaa	8	
		Arg-Xaa		
	Chymotrypsin	Tyr-Xaa	7.0-9.0	
		Phe-Xaa		
		Trp-Xaa		
	Elastase	Ala-Xaa	8.8	
		Val-Xaa		
		Leu-Xaa		
		Ile-Xaa		
		Gly-Xaa		
		Ser-Xaa		
	Kallikrein	Arg-Xaa	7.0-8.0	
		Phe-Arg-Xaa		preferred
		Leu-Arg-Xaa		preferred
10	Carboxypeptidase	Xaa-Xaa	7.0-9.0	from C-terminal

Optional Ingredients - The Absorption Enhancer

When used, the absorption enhancers are preferably present in a quantity that constitutes from 0.1 to 20.0 percent by weight, relative to the overall weight of the pharmaceutical composition (exclusive of the enteric
15 coating). Preferred absorption enhancers are surface

active agents which act both as solubility enhancers and uptake enhancers. Generically speaking, "solubility enhancers" improve the ability of the components of the invention to be solubilized in either the aqueous
5 environment into which they are originally released or into the lipophilic environment of the mucous layer lining the intestinal walls, or both. "Transport (uptake) enhancers" (which are frequently the same surface active agents used as solubility enhancers) are those which
10 facilitate the ease by which peptide agents cross the intestinal wall.

One or more absorption enhancers may perform one function only (e.g., solubility), or one or more absorption enhancers may perform the other function only
15 (e.g., uptake), within the scope of the invention. It is also possible to have a mixture of several compounds some of which provide improved solubility, some of which provide improved uptake and/or some of which perform both. Without intending to be bound by theory, it is believed
20 that uptake enhancers may act by (1) increasing disorder of the hydrophobic region of the membrane exterior of intestinal cells, allowing for increased transcellular transport; or (2) leaching membrane proteins resulting in increased transcellular transport; or (3) widening pore
25 radius between cells for increased paracellular transport.

Surface active agents are believed to be useful both

as solubility enhancers and as uptake enhancers. For example, detergents are useful in (1) solubilizing all of the active components quickly into the aqueous environment where they are originally released, (2) enhancing
5 lipophilicity of the components of the invention, especially the peptide active agent, aiding its passage into and through the intestinal mucus, (3) enhancing the ability of the normally polar peptide active agent to cross the epithelial barrier of the brush border membrane;
10 and (4) increasing transcellular or paracellular transport as described above.

When surface active agents are used as the absorption enhancers, it is preferred that they be free flowing powders for facilitating the mixing and loading of
15 capsules during the manufacturing process. Because of inherent characteristics of salmon calcitonin and other peptides (e.g., their isoelectric point, molecular weight, amino acid composition, etc.) certain surface active agents interact best with certain peptides. Indeed, some
20 can undesirably interact with the charged portions of salmon calcitonin and prevent its absorption, thus undesirably resulting in decreased bioavailability. It is preferred, when trying to increase the bioavailability of salmon calcitonin or other peptides that any surface
25 active agent used as an absorption enhancer be selected from the group consisting of (i) anionic surface active agents that are cholesterol derivatives (e.g., bile

acids), (ii) cationic surface agents (e.g., acyl
carnitines, phospholipids and the like), (iii) non-ionic
surface active agents, and (iv) mixtures of anionic
surface active agents (especially those having linear
5 hydrocarbon regions) together with negative charge
neutralizers. Negative charge neutralizers include but
are not limited to acyl carnitines, cetyl pyridinium
chloride, and the like. It is also preferred that the
absorption enhancer be soluble at acid pH, particularly in
10 the 3.0 to 5.0 range.

One especially preferred combination that has worked
well with salmon calcitonin mixes cationic surface active
agents with anionic surface active agents that are
cholesterol derivatives, both of which are soluble at acid
15 pH.

A particularly preferred combination is an acid
soluble bile acid together with a cationic surface active
agent. An acyl carnitine and sucrose ester is a good
combination. When a particular absorption enhancer is
20 used alone, it is preferred that it be a cationic surface
active agent. Acyl carnitines (e.g., lauroyl carnitine),
phospholipids and bile acids are particularly good
absorption enhancers, especially acyl carnitine. Anionic
surfactants that are cholesterol derivatives are also used
25 in some embodiments. It is the intent of these
preferences to avoid interactions with the peptide agent

that interfere with absorption of peptide agent into the blood.

To reduce the likelihood of side effects, preferred detergents, when used as the absorption enhancers of the invention, are either biodegradable or reabsorbable (e.g.,
5 biologically recyclable compounds such as bile acids, phospholipids, and/or acyl carnitines), preferably biodegradable. Acylcarnitines are believed particularly useful in enhancing paracellular transport. When a bile
10 acid (or another anionic detergent lacking linear hydrocarbons) is used in combination with a cationic detergent, salmon calcitonin is better transported both to and through the intestinal wall.

Preferred absorption enhancers include: (a)
15 salicylates such as sodium salicylate, 3-methoxysalicylate, 5-methoxysalicylate and homovanilate;
(b) bile acids such as taurocholic, tauorodeoxycholic, deoxycholic, cholic, glycholic, lithocholate, chenodeoxycholic, ursodeoxycholic,ursocholic,
20 dehydrocholic, fusidic, etc.; (c) non-ionic surfactants such as polyoxyethylene ethers (e.g., Brij 36T, Brij 52, Brij 56, Brij 76, Brij 96, Texaphor A6, Texaphor A14, Texaphor A60 etc.), p-t-octyl phenol polyoxyethylenes
(Triton X-45, Triton X-100, Triton X-114, Triton X-305
25 etc.) nonylphenoxypoloxyethylenes (e.g., Igepal CO series), polyoxyethylene sorbitan esters (e.g., Tween-20,

Tween-80 etc.); (d) anionic surfactants such as dioctyl sodium sulfosuccinate; (e) lyso-phospholipids such as lysolecithin and lysophosphatidylethanolamine; (f) acylcarnitines, acylcholines and acyl amino acids such as
5 lauroylcarnitine, myristoylcarnitine, palmitoylcarnitine, lauroylcholine, myristoylcholine, palmitoylcholine, hexadecyllysine, N-acylphenylalanine, N-acylglycine etc.;
g) water soluble phospholipids; (h) medium-chain glycerides which are mixtures of mono-, di- and
10 triglycerides containing medium-chain-length fatty acids (caprylic, capric and lauric acids); (i) ethylene-diaminetetraacetic acid; (j) cationic surfactants such as cetylpyridinium chloride; (k) fatty acid derivatives of polyethylene glycol such as Labrasol, Labrafac, etc.; and
15 (l) alkylsaccharides such as lauryl maltoside, lauroyl sucrose, myristoyl sucrose, palmitoyl sucrose, etc.

In some preferred embodiments, and without intending to be bound by theory, cationic ion exchange agents (e.g., detergents) are included to provide solubility enhancement
20 by another possible mechanism. In particular, they may prevent the binding of salmon calcitonin or other peptide active agents to mucus. Preferred cationic ion exchange agents include protamine chloride or any other polycation.

Other Optional Ingredients

25 It is preferred that a water-soluble barrier separate the protease inhibitors and/or the pH-lowering agent from

the acid resistant protective vehicle. A conventional pharmaceutical capsule can be used for the purpose of providing this barrier. Many water soluble barriers are known in the art and include, but are not limited to,
5 hydroxypropyl methylcellulose and conventional pharmaceutical gelatins.

In some preferred embodiments, another peptide (such as albumin, casein, soy protein, other animal or vegetable proteins and the like) is included to reduce non-specific
10 adsorption (e.g., binding of peptide to the intestinal mucus barrier) thereby lowering the necessary concentration of the expensive peptide active agent. When added, the peptide is preferably from 1.0 to 10.0 percent by weight relative to the weight of the overall
15 pharmaceutical composition (excluding protective vehicle). Preferably, this second peptide is not physiologically active and is most preferably a food peptide such as soy bean peptide or the like. Without intending to be bound by theory, this second peptide may also increase
20 bioavailability by acting as a protease scavenger that desirably competes with the peptide active agent for protease interaction. The second peptide may also aid the active compound's passage through the liver.

All pharmaceutical compositions of the invention may
25 optionally also include common pharmaceutical diluents, glidants, lubricants, gelatin capsules, preservatives,

colorants and the like in their usual known sizes and amounts.

The Protective Vehicle

Any carrier or vehicle that protects the peptide agent from stomach proteases and then dissolves so that the other ingredients of the invention may be released in the intestine is suitable. Many such enteric coatings are known in the art, and are useful in accordance with the invention. Examples include cellulose acetate phthalate, hydroxypropyl methylethylcellulose succinate, hydroxypropyl methylcellulose phthalate, carboxyl methylethylcellulose and methacrylic acid-methyl methacrylate copolymer. In some embodiments, the active peptide, absorption enhancers such as solubility and/or uptake enhancer(s), and pH-lowering compound(s), are included in a sufficiently viscous protective syrup to permit protected passage of the components of the invention through the stomach.

Suitable enteric coatings for protecting the peptide agent from stomach proteases may be applied, for example, to capsules after the remaining components of the invention have been loaded within the capsule. In other embodiments, enteric coating is coated on the outside of a tablet or coated on the outer surface of particles of active components which are then pressed into tablet form, or loaded into a capsule, which is itself preferably

coated with an enteric coating.

It is very desirable that all components of the invention be released from the carrier or vehicle, and solubilized in the intestinal environment as simultaneously as possible. It is preferred that the vehicle or carrier release the active components in the small intestine where uptake enhancers that increase transcellular or paracellular transport are less likely to cause undesirable side effects than if the same uptake enhancers were later released in the colon. It is emphasized, however, that the present invention is believed effective in the colon as well as in the small intestine. Numerous vehicles or carriers, in addition to the ones discussed above, are known in the art. It is desirable (especially in optimizing how simultaneously the components of the invention are released) to keep the amount of enteric coating low. Preferably, the enteric coating adds no more than 30% to the weight of the remainder of pharmaceutical composition (the "remainder" being the pharmaceutical composition exclusive of enteric coating itself). More preferably, it adds less than 20%, especially from 12% to 20% to the weight of the uncoated composition. The enteric coating preferably should be sufficient to prevent breakdown of the pharmaceutical composition of the invention in 0.1N HCl for at least two hours, then capable of permitting complete release of all contents of the pharmaceutical composition within thirty

minutes after pH is increased to 6.3 in a dissolution bath in which said composition is rotating at 100 revolutions per minute.

Other Preferences

5 It is preferred that the weight ratio of pH-lowering agent(s) and/or protease inhibitors to absorption enhancer(s), when present, be between 3:1 and 20:1, preferably 4:1-12:1, and most preferably 5:1-10:1. The total weight of all pH-lowering agents and/or protease
10 inhibitors and the total weight of all absorption enhancers in a given pharmaceutical composition is included in the foregoing preferred ratios. For example, if a pharmaceutical composition includes two pH-lowering agents and three absorption enhancers, the foregoing
15 ratios will be computed on the total combined weight of both pH-lowering agents and the total combined weight of all three absorption enhancers.

 It is preferred that the pH-lowering agent and/or protease inhibitor, the peptide active agent and the
20 absorption enhancer, when present, (whether single compounds or a plurality of compounds in each category) be uniformly dispersed in the pharmaceutical composition. In one embodiment, the pharmaceutical composition comprises granules that include a pharmaceutical binder having the
25 peptide active agent, the pH-lowering agent and the absorption enhancer uniformly dispersed within said

binder. Preferred granules may also consist of an acid core, surrounded by a uniform layer of organic acid, a layer of enhancer and a layer of peptide that is surrounded by an outer layer of organic acid. Granules
5 may be prepared from an aqueous mixture consisting of pharmaceutical binders such as polyvinyl pyrrolidone or hydroxypropyl methylcellulose, together with the pH-lowering agents, absorption enhancers and peptide active agents of the invention.

10 Manufacturing Process

A preferred pharmaceutical composition of the invention includes a size OO gelatin capsule filled with 0.25 mg. of salmon calcitonin linked to an MT, 400 mg. of granular citric acid (available for example from Archer
15 Daniels Midland Corp.), 50 mg. of taurodeoxycholic acid (available for example from SIGMA), 50 mg. lauroyl carnitine (SIGMA).

All of the ingredients are preferably for eventual insertion into the gelatin capsule, and are preferably
20 powders which may be added to a blender in any order. Thereafter, the blender is run for about three minutes until the powders are thoroughly intermixed. Then the mixed powders are loaded into the large end of the gelatine capsules. The other end of the capsule is then
25 added, and the capsule snapped shut. 500 or more such capsules may be added to a coating device (e.g., Vector

LDCS 20/30 Laboratory Development Coating System
(available from Vector Corp., Marion, Iowa)).

An enteric coating solution is made as follows.
Weigh 500 grams of EUDRAGIT L30 D-55 (a methacrylic acid
5 copolymer with methacrylic acid methyl ester, an enteric
coating available from RÖHM Tech Inc., Maidan, Mass.).
Add 411 grams distilled water, 15 grams triethyl citrate
and 38 grams talc. This amount of coating will be
sufficient to coat about 500 size 00 capsules.

10 The capsules are weighed and placed into the drum of
the coating machine. The machine is turned on to rotate
the drum (now containing capsules) at 24-28 rpm. The
temperature of inlet sprayer is preferably about 45°C.
Exhaust temperatures are preferably about 30°C. Uncoated
15 capsule temperature is preferably about 25°C. Air flow is
about 38 cubic feet per minute.

A tube from the machine is then inserted into the
coating solution prepared as discussed above. The pump is
then turned on for feeding solution into the coating
20 device. Coating then proceeds automatically. The machine
can be stopped at any time to weigh capsules to determine
if the coating amount is sufficient. Usually coating is
allowed to proceed for 60 minutes. The pump is then
turned off for about five minutes while the machine is
25 still running to help dry the coated capsules. The

machine can then be turned off. The capsule coating is then complete, although it is recommended that the capsules be air dried for about two days.

Because of the enhanced bioavailability provided by the present invention, the concentration of expensive salmon calcitonin in the pharmaceutical preparation of the invention may be kept relatively low. Specific formulation examples are set forth in examples *infra*.

Treatment of Patients

When salmon calcitonin is chosen as active ingredient for treatment of osteoporosis, periodic administration is recommended. Salmon calcitonin is metabolized quickly with a half-life of only 20-40 minutes following subcutaneous administration in man. However, its beneficial effect on osteoclasts is much longer lasting, and may last for more than 24 hours notwithstanding rapid decrease in blood levels. There is usually no detectable blood levels more than two hours after injection of salmon calcitonin at conventional dosages. Accordingly, periodic administration of one dose about 5 days per week is preferred. Subcutaneous administration of salmon calcitonin (100 International units) has frequently resulted in peak serum concentration of about 250 picograms per milliliter. Nasally administered salmon calcitonin (200 International units) has proven effective against osteoporosis at peak levels as low as 10 picograms

per milliliter. Some patients report some gastrointestinal distress at high peak levels (e.g., at or above 200 picograms per milliliter). Accordingly, it is preferred that serum salmon calcitonin peak between 10 and 150 picograms per milliliter, more preferably between 10 and 50 picograms per milliliter. The serum levels may be measured by radioimmunoassay techniques known in the art. The attending physician may monitor patient response, salmon calcitonin blood levels, or surrogate markers of bone disease (such as urinary pyridinoline or deoxypyridinoline), especially during the initial phase of treatment (1-6 months). He may then alter the dosage somewhat to account for individual patient metabolism and response.

It is preferred that a single capsule be used at each administration because a single capsule best provides simultaneous release of the polypeptide, pH-lowering agent and absorption enhancers. This is highly desirable because the acid is best able to reduce undesirable proteolytic attack on the polypeptide when the acid is released in close time proximity to release of the polypeptide. Near simultaneous release is best achieved by administering all components of the invention as a single pill or capsule. However, the invention also includes, for example, dividing the required amount of acid and enhancers, when used, among two or more capsules which may be administered together such that they together

provide the necessary amount of all ingredients.

"Pharmaceutical composition," as used herein includes a complete dosage appropriate to a particular administration to a human patient regardless of how it is subdivided so long as it is for substantially simultaneous administration.

Example 1 -Effect of Carboxy Terminal Amidation on the Oral Bioavailability of Salmon Calcitonin (sCT).

A study was carried out in a dog model to compare the pharmacokinetic parameters of orally delivered glycine-extended sCT (sCTgly) with those of amidated sCT (sCT-NH₂).

Eight adult male Beagle dogs, weighing between 12 and 16 kg, were used in this study. Dogs were fasted overnight prior to administration of the test peptide, but were allowed free access to water. A wash-out period of at least 1 week occurred between experiments for each dog. Each dog received an orally administered, enteric coated gelatin capsule that contained 1.11 mg of sCTgly in week 1 and 1.11 mg of sCT-NH₂ in week 2. The total composition of each capsule is shown in Table 4. Prior to capsule administration, a 20-gauge intravenous (IV) catheter was inserted into a brachial vein for the collection of blood samples. Two pre-dose samples of 3 ml each were collected from the brachial vein.

Table 4 - The Composition of sCT-gly and sCTNH₂ Capsules

Capsule	Granular Citric Acid (mg)	LLC (mg)	sCT-gly (mg)	sCT-NH ₂ (mg)	Talc (mg)
sCT-gly capsule	596	62	1.11		30
sCTNH ₂ capsule	576	58		1.11	29

5 After administration of the capsule, 3 ml blood
samples were collected from the brachial vein at 15 minute
intervals up to 240 minutes post-administration. Blood
samples were collected into new heparinized Monovette
sampling syringes. Samples were placed on ice before
10 being centrifuged for 10 minutes at approximately 2750 rpm
at 2-8°C. The plasma supernatant was transferred to
color-coded microcentrifuge tubes labeled with the time
point and stored frozen at -20°C prior to analysis to
determine the concentration of sCTgly or sCT-NH₂.

15 The concentration of sCTgly in plasma was determined
by radioimmunoassay with an RIA kit from Peninsula
Laboratories. sCT-NH₂ concentration in plasma was
determined by a sandwich ELISA immunoassay using a kit
from Diagnostic Systems Laboratories Inc. From the
20 pharmacokinetic profile of sCTgly or sCT-NH₂ in plasma,
the parameters of C_{max} (peak of plasma concentration in
pg/ml) and AUC (Area under the Curve) were determined.
All measured values were normalized for a 1 mg peptide
dose for either of the two peptides. The mean for each of
25 these parameters is shown in Table 5.

Table 5

Peptide	Mean Cmax* \pm SEM (pg/ml)	Mean AUC* \pm SERM (pg•min/ml)
sCTgly	485 \pm 106	25,125 \pm 5,525
SCT-NH ₂	3,199 \pm 602	148,000 \pm 18,200

5 * Adjusted to a 1 mg dose

The mean Cmax of sCT with a C-terminal amide is 6.6 times greater than that of sCTgly. The mean AUC, which is an indirect measure of bioavailability, is 5.9 times greater for SCT-NH₂ than for sCTgly. Thus, for these two
10 peptides, which are identical except for the presence of a glycine or an amide group at the C-terminus, there is a dramatic difference in the amount of peptide measured in plasma after oral delivery, and this can be directly attributed to the presence of the C-terminal amide group.

15 **Example 2: Comparison of the Bioavailability of Amidated and Non-Amidated Analogs of Parathyroid Hormone (PTH)**

Two separate studies were carried out in a dog model to determine the pharmacokinetic parameters of orally delivered PTH analogs. The analog used in the first study
20 was PTH1-34-OH. In the second study, a slightly smaller analog, PTH1-31NH₂, was used. Apart from the small difference in size (three amino acids), the main difference between the two molecules is that the 1-34 peptide has a free acid at the C-terminus and the 1-31
25 peptide has an amidated C-terminus.

Eight adult male Beagle dogs, weighing between 12 and 16 kg, were used in the study for PTH1-34-OH . In the PTH1-31NH₂ study, six of these same dogs were used. Dogs were fasted overnight prior to administration of the test peptide, but were allowed free access to water. A wash-out period of at least 1 week occurred between experiments for each dog. Each dog received an orally administered, enteric coated gelatin capsule that contained 2.64 mg of PTH1-34-OH in the first study and 2.38 mg of PTH1-31NH₂ in the second study. The total composition of each capsule is shown in Table 6. Prior to capsule administration, a 20-gauge intravenous (IV) catheter was inserted into a brachial vein for the collection of blood samples. Two pre-dose samples of 3 ml each were collected from the brachial vein.

**Table 6 - The Composition of PTH1-34-OH
and PTH1-31NH₂ Capsules**

Capsule	Granular Citric Acid (mg)	LLC (mg)	PTH1-34-OH (mg)	PTH1-31NH ₂ (mg)	Talc (mg)
PTH1-34-OH Capsule	472	47	2.64		24
PTH1-31NH ₂ Capsule	576	58		2.38	29

After administration of the capsule, 3 mL blood samples were collected from the brachial vein at 15 minute intervals up to 240 minutes post-administration. Blood samples were collected into new heparinized Monovette

sampling syringes. The samples were placed on ice before being centrifuged for 10 minutes at approximately 2750 rpm at 2-8°C. The plasma supernatant was transferred to color-coded microcentrifuge tubes labeled with the time point and stored frozen at -20°C prior to analysis of the concentration of PTH1-34-OH or PTH1-31NH₂.

The concentration of PTH1-34-OH in plasma was determined using a RIA kit from Peninsula Laboratories. PTH1-31NH₂ was quantified using a competitive ELISA developed at Unigene Laboratories. From the pharmacokinetic profile of PTH1-34-OH or PTH1-31NH₂ in plasma, the parameters of C_{max} (peak of plasma concentration in pg/ml) and AUC (Area under the Curve) were calculated. The mean values for each of these parameters is shown in Table 7.

Table 7

Peptide	Mean C _{max} * ± SEM (pg/ml)	Mean AUC* ± SEM (pg•min/ml)
PTH1-34-OH	314 ± 117	11,893 ± 3,366
PTH1-31NH ₂	2,155 ± 456	116,400 ± 32,100

* Adjusted to a 1 mg dose

The mean C_{max} of PTH1-31NH₂ is approximately 6.25 times greater than that of PTH1-34-OH, and the mean AUC, an indirect measure of bioavailability, is 9.8 times greater for PTH1-31NH₂. Although the PTH1-31NH₂ molecule is smaller by 3 amino acids than PTH1-34-OH, this small

difference in molecular weight between the two peptides (3718 Daltons and 4118 Daltons respectively) does not account for the difference seen in bioavailabilities. Therefore, the important difference between the two peptides is the presence or absence of the C-terminal amide group.

Example 3 - Comparison of the Bioavailability of an Analog of Parathyroid Hormone, PTH1-34, with or without a C-terminal Amide Group, by Intraduodenal Administration in Rats

Female Sprague-Dawley rats (250-275 g) (n=6 for PTH1-34-OH and n=7 for PTH1-34NH₂) were anesthetized with ketamine and xylazine prior to the insertion of a cannula in the carotid artery. The cannula was fitted to a three way valve through which blood was sampled and replaced with physiological saline. A midline incision was made in the abdominal cavity and 0.5 ml of formulation was injected directly into the exposed duodenum. The formulation for each peptide contained citric acid (0.5 M), lauroylcarnitine (10 mg/ml), salmon calcitonin (included as an internal marker) (0.5 mg/ml) and either PTH1-34-OH or PTH1-34NH₂ (0.5 mg/ml). Blood (0.5 ml) was collected before and at 5, 15, 30, 60 and 120 minutes after the administration of the formulations. Samples of blood were centrifuged for 10 minutes at 2600 x g, and the resulting plasma supernatant was stored at -20°C. The concentration of the peptides in plasma was determined by a competitive enzyme linked

immunoassay (ELISA). The absolute bioavailability (i.e., relative to an intravenous dose for each peptide) was calculated from the areas under the curve obtained from plots of the plasma concentration of PTH1-34-OH or PTH1-34NH₂ as a function of time.

PTH1-34-OH and PTH1-34NH₂ were rapidly absorbed from the rat duodenum within 5 minutes after their administration. The maximum concentration of PTH 1-34-OH was 3.05 ng/ml and that of PTH1-34NH₂ was 26.7 ng/ml, which was nearly 9 times greater than the free acid form of PTH (1-34). After 60 minutes, the concentration of PTH1-34NH₂ was still nearly 9 times greater than that of PTH1-34-OH (Table 8). The absolute bioavailability of PTH1-34NH₂ was 3.68% and that of PTH1-34-OH was 0.45%. These results suggest that the substitution of the amide group at the C-terminus for the OH group improved the maximum peptide concentration in plasma by 8.75 fold and the absolute bioavailability of PTH1-34 by 8.2 fold.

able 8 - Effect of C-Terminal Amide on the Pharmacokinetic
Profile of PTH1-34

	Time	PTH1-34-OH	PTH1-34NH ₂
	(Min)	ng/ml \pm standard error	ng/ml \pm standard error
5	0	0.00	0.00
	5	2.69 \pm 1.35	26.70 \pm 7.84
	15	3.05 \pm 1.31	21.03 \pm 4.07
	30	1.90 \pm 0.81	13.13 \pm 3.36
	60	0.62 \pm 0.38	5.39 \pm 3.08
10	120	0.81 \pm 0.35	1.18 \pm 1.08
	Absolute Bioavailability (%)	0.45 \pm 0.18	3.68 \pm 0.76

Example 4 - Effect of C-terminal amide on the
Intraduodenal Absorption of LHRH in Rats

15 The effect of C-terminal amidation on the absorption
of luteinizing hormone-releasing hormone (LHRH-NH₂) from
the duodenum of anesthetized rats was examined. In this
study the absorption characteristics of LHRH-NH₂, a
naturally occurring C-terminal amidated decapeptide were
20 compared with that of LHRH-COOH, a decapeptide with the
same amino acid sequence as that of LHRH-NH₂ except that
the C-terminal amino acid of LHRH-COOH is gly-COOH instead
of gly-NH₂. Twelve female rats were anesthetized and
implanted with a cannula in the carotid artery for taking
25 blood samples at various times. Six rats were injected in
the duodenum through a 27 gauge needle with 0.5 mL of
LHRH-NH₂ (5 mg/mL) in 0.5M citric acid and

lauroylcarnitine (10 mg/mL) and six rats with injected in the duodenum with 0.5 mL LHRH-COOH (5 mg/mL) in the same formulation. Samples of blood were taken prior to the administration of formulated LHRH-NH₂ or LHRH-COOH and at 5, 15, 30, 60, and 120 minutes after peptide administration. The resulting plasma samples were analyzed for LHRH-NH₂ or LHRH-COOH by high performance liquid chromatography equipped with a fluorescence detector to measure the concentration of peptide in plasma. The maximum concentration (C_{max}) of amidated and non-amidated LHRH was detected in plasma five minutes after peptide administration. Although equal amounts of both forms of LHRH were administered to rats, 5 times as much amidated LHRH, LHRH-NH₂, was detected in plasma at five minutes than the free acid form, LHRH-COOH (Table 9). The area under the curve (AUC), a measure of the extent of peptide absorption and bioavailability, was 6 times greater for amidated LHRH than the free acid form of LHRH (Table 9). These results indicate that amidated peptides in a formulation containing an acid and an enhancer have greater bioavailability than non-amidated peptides.

Table 9 - Effect of C-terminal amide on the Intraduodenal
Absorption of LHRH in Rats

	min	LHRH-NH ₂	LHRH-COOH
	0	ng/mL \pm sem	ng/mL \pm sem
5	5	0	0
	15	3276 \pm 893	654 \pm 103
	30	2897 \pm 612	391 \pm 81
	60	1282 \pm 282	163 \pm 68
	120	382 \pm 103	56 \pm 19
10	Cmax	3276 \pm 893	654 \pm 103
	AUC	109350 \pm 23652	17731 \pm 4002

Although the present invention has been described in relation to particular embodiments thereof, many other variations and modifications and other uses will become apparent to those skilled in the art. The present invention therefore is not limited by the specific disclosure herein, but only by the claims.